Caris Life Sciences (CAI) traded lower as the market focused on a recently disclosed refinancing that materially increases the company’s debt capacity. In an April 1, 2026 senior secured credit agreement, Caris put in place a $400 million term loan and layered in additional borrowing optionality via a committed delayed-draw facility of up to $300 million and an uncommitted incremental facility of up to $500 million.

Even though the transaction replaced an older credit agreement, the size and pricing of the new facilities are drawing attention. The term loan is priced at term SOFR plus 5.00% (or base rate plus 4.00%), and the agreement includes a minimum qualified cash covenant requiring $50 million at each fiscal quarter-end—terms that can heighten investor sensitivity to liquidity and leverage as the company invests for growth.

The initial $400 million term loan funded at closing and matures in April 2031. The delayed-draw facility is available through August 2027 and is restricted to permitted acquisitions, while the incremental facility adds further potential capacity. The facilities are senior secured and guaranteed by certain subsidiaries, with liens on substantially all tangible and intangible personal property, reinforcing lender protections and underscoring the debt-like nature of the capital stack.

Traders will be looking for follow-through disclosures on how much of the additional capacity Caris ultimately draws and whether management uses the acquisition-only delayed-draw facility. With the next earnings report currently scheduled for June 3, 2026, investors are likely to focus on updated 2026 outlook, interest expense implications, and any commentary on liquidity headroom versus the quarterly minimum-cash covenant.